Companies › Amyloid Solution
1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AS-S603 Small molecule targeting amyloid-beta and tau aggregates | APP, MAPT | Phase 1 | Healthy | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06786676 | AS-S603 | Phase 1 | Healthy | Neurology | Dec 2026 |
Roche Alnylam Pharmaceuticals Nuravax Eli Lilly Eisai Acumen Pharmaceuticals JYAMS PET Research & Development HTA Eli Radiopharma Bristol-Myers Squibb
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.